Analysts Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Price Target at $11.67

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has received a consensus rating of “Hold” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $11.6667.

A number of analysts have recently issued reports on NMTC shares. LADENBURG THALM/SH SH lifted their price objective on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings raised NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th.

NeuroOne Medical Technologies Trading Down 2.4%

NMTC stock opened at $1.65 on Thursday. The company’s 50 day moving average is $2.81 and its 200 day moving average is $3.96. The stock has a market cap of $14.36 million, a price-to-earnings ratio of -1.94 and a beta of 0.61. NeuroOne Medical Technologies has a 1-year low of $1.61 and a 1-year high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 99.43%. The company had revenue of $1.86 million for the quarter, compared to the consensus estimate of $2.58 million. As a group, sell-side analysts forecast that NeuroOne Medical Technologies will post -0.36 EPS for the current fiscal year.

Insider Activity

In other news, Director Mark Christianson sold 10,000 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total transaction of $31,800.00. Following the transaction, the director directly owned 20,692 shares in the company, valued at approximately $65,800.56. This represents a 32.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 11.80% of the company’s stock.

Institutional Trading of NeuroOne Medical Technologies

Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new stake in NeuroOne Medical Technologies in the first quarter worth approximately $84,000. XTX Topco Ltd bought a new stake in shares of NeuroOne Medical Technologies in the 2nd quarter worth approximately $51,000. Vanguard Group Inc. lifted its holdings in shares of NeuroOne Medical Technologies by 31.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock worth $1,403,000 after acquiring an additional 375,639 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of NeuroOne Medical Technologies in the 3rd quarter valued at $88,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of NeuroOne Medical Technologies in the 3rd quarter valued at $47,000. Institutional investors own 16.07% of the company’s stock.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.